Date
- Wednesday, 17 November 2010, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
Experts in the field of paediatric rheumatology from Europe and the United States of America are attending this meeting together with representatives of regulators from both sides of Atlantic. All aspects of development of medicines for children with juvenile idiopathic arthritis are being discussed, from non-clinical studies to pharmacovigilance measures. The conclusions of this meeting will create a basis for standardisation of paediatric investigation plans for chronic idiopathic arthritis, which has been found necessary by all stakeholders.